WHAT IS CLAIMED IS:

1. A method of improving an asthma questionnaire score in an asthmatic patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

2. The method of claim 1, wherein the questionnaire assesses at least one symptom selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

3. The method of claim 2, wherein the questionnaire assesses night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and rescue medication use.

4. The method of claim 2, wherein the questionnaire assess daytime symptom frequency, daytime symptom severity, and nighttime severity.

5. The method of claim 1, wherein the asthma questionnaire is the asthma control questionnaire (ACQ).

6. The method of claim 1, wherein the asthma questionnaire is the asthma control questionnaire-6 (ACQ-6).

7. The method of claim 1, wherein the asthma questionnaire is the asthma quality of life questionnaire (AQLQ).

8. A method of treating asthma, comprising administering to an asthma patient an effective amount of benralizumab or an antigen-binding fragment thereof, wherein the patient has a blood eosinophil count of at least 300 cells/μl prior to the administration.

9. A method of treating asthma, comprising administering to an asthma patient an effective amount of benralizumab or an antigen-binding fragment thereof, wherein the patient has a forced expiratory volume in one second (FEV_1) of at least 75% predicted value prior to the administration.

10. A method of treating asthma, comprising administering at least two doses of benralizumab or an antigen-binding fragment thereof to an asthma patient.

11. The method of any one of claims 8-10, wherein the administration improves an asthma symptom in the patient.

12. The method of claim 11, wherein the asthma symptom is selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

13. The method of any one of claims 5 and 8-12, wherein the patient's ACQ score decreases.

14. The method of any one of claims 6 and 8-12, wherein the patient's ACQ-6 score decreases.

15. The method of claim 14, wherein the patient's ACQ-6 decreases within 7 weeks of the first administration.

16. The method of any one of claims 1-7 or 9-15, wherein the asthma is eosinophilic asthma.

17. The method of any one of claims 1-7 or 9-15, wherein the patient has a blood eosinophil count of at least 300 cells/μl.

18. The method of any one of claims 1-8 or 10-17, wherein, the patient has a forced expiratory volume in one second (FEV_1) of at least 75% predicted value prior to the administration.

19. The method of any one of claims 1-18, wherein the patient has an asthma control questionnaire score of at least 1.5 prior to the administration

20. The method of any one of claims 1-9 or 11-19, wherein at least two doses of the anti-benralizumab or antigen-binding fragment thereof are administered to the patient.

21. The method of any one of claims 6 or 14-20, wherein the patient's ACQ-6 score decreases following administration of the benralizumab or antigen-binding fragment thereof.

22. The method of any one of claims 6 or 14-21, wherein the ACQ-6 score is decreased by at least 0.5.

23. The method of claim 22, wherein the ACQ-6 score is decreased by at least 1.

24. The method of claim 23, wherein the ACQ-6 score is decreased by at least 2.

25. The method of any one of claims 1-24, wherein the patient uses high-dose inhaled corticosteroids (ICS).

26. The method of any one of claims 1-25, wherein the patient uses long-acting β2 agonists (LABA).

27. The method of any one of claims 1-26, wherein the patient has a history of exacerbations.

28. The method of claim 27, wherein the history of exacerbations comprises at least two exacerbations in the year prior to the administration of the benralizumab or antigen-binding fragment thereof.

29. The method of claim 26 or 27, wherein the history of exacerbations comprises no more than six exacerbations in the year prior to the administration of the benralizumab or antigen-binding fragment thereof.

30. The method of any one of claims 1-29, wherein the benralizumab or antigen-binding fragment thereof is administered at about 2 mg to about 100 mg per dose.

31. The method of claim 30, wherein the benralizumab or antigen-binding fragment thereof is administered at about 20 mg per dose.

32. The method of claim 30, wherein the benralizumab or antigen-binding fragment thereof is administered at about 30 mg per dose.

33. The method of claim 30, wherein the benralizumab or antigen-binding fragment thereof is administered at about 100 mg per dose.

34. The method of any one of claims 1-33, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks to once every twelve weeks.

35. The method of claim 34, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks.

36. The method of claim 34, wherein the benralizumab or antigen-binding fragment thereof is administered once every eight weeks.

37. The method of claim 34, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.

38. The method of any one of claims 1 to 37, wherein the benralizumab or antigen-binding fragment thereof is administered parenterally.

39. The method of claim 38, wherein the benralizumab or antigen-binding fragment thereof is administered subcutaneously.

40. The method of any one of claims 1 to 39, wherein the benralizumab or antigen-binding fragment thereof is administered in addition to corticosteroid therapy.

41. A method of improving an asthma questionnaire score in an asthmatic patient, comprising administering to an asthma patient 20-100 mg of benralizumab or an antigen-binding fragment thereof, wherein the patient has an blood eosinophil count of at least 300 cells/μl prior to the administration.

42. The method of claim 41, comprising administering 20 mg of benralizumab or an antigen-binding fragment thereof.

43. The method of claim 42, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.

44. The method of claim 41, comprising administering 30 mg of benralizumab or an antigen-binding fragment thereof.

45. The method of claim 44, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks for eight weeks and then once every eight weeks.

46. The method of claim 44, wherein the benralizumab or antigen-binding fragment thereof is administered once every four weeks.

47. The method of claim 41, comprising administering 100 mg of benralizumab or an antigen-binding fragment thereof.

48. The method of claim 47, wherein the benralizumab or an antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.

49. A method of treating asthma in an asthma patient, comprising administering to the patient a dose of at least 2 and less than 100 mg of benralizumab or an antigen-binding fragment thereof.

50. The method of claim 49, wherein 20 mg of the benralizumab or antigen-binding fragment is administered.

51. The method of claim 49, wherein 30 mg of the benralizumab or antigen-binding fragment is administered.

52. The method of claim 49, wherein a dose of at least 20 and less than 100 mg of the benralizumab or antigen-binding fragment is administered.

53. The method of claim 49, wherein a dose of at least 30 and less than 100 mg of the benralizumab or antigen-binding fragment is administered.

54. The method of any one of claims 49-53, wherein administration of the benralizumab or antigen-binding fragment improves an asthma symptom in the patient.

55. The method of claim 54, wherein the symptom is selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

56. The method of any one of claims 49-55, wherein administration of the benralizumab or antigen-binding fragment decreases the patient's ACQ-6 score within four weeks of the first administration.

57. The method of any one of claims 49-56, wherein the administration is subcutaneous.

WHAT IS CLAIMED IS:

1. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for improving an asthma questionnaire score in an asthmatic patient, comprising administering to the patient an effective amount of the medicament.

2. The use of claim 1, wherein the questionnaire assesses at least one symptom selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

3. The use of claim 2, wherein the questionnaire assesses night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and rescue medication use.

4. The use of claim 2, wherein the questionnaire assess daytime symptom frequency, daytime symptom severity, and nighttime severity.

5. The use of claim 1, wherein the asthma questionnaire is the asthma control questionnaire (ACQ).

6. The use of claim 1, wherein the asthma questionnaire is the asthma control questionnaire-6 (ACQ-6).

7. The use of claim 1, wherein the asthma questionnaire is the asthma quality of life questionnaire (AQLQ).

8. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, comprising administering to an asthma patient an effective amount of the medicament, wherein the patient has a blood eosinophil count of at least 300 cells/μl prior to the administration.

9. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, comprising administering to an asthma patient an effective amount of b the medicament, wherein the patient has a forced expiratory volume in one second (FEV_1) of at least 75% predicted value prior to the administration.

10. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, comprising administering at least two doses of the medicament to an asthma patient.

11. The use of any one of claims 8-10, wherein the administration improves an asthma symptom in the patient.

12. The use of claim 11, wherein the asthma symptom is selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

13. The use of any one of claims 5 and 8-12, wherein the patient's ACQ score decreases.

14. The use of any one of claims 6 and 8-12, wherein the patient's ACQ-6 score decreases.

15. The use of claim 14, wherein the patient's ACQ-6 decreases within 7 weeks of the first administration.

16. The use of any one of claims 1-7 or 9-15, wherein the asthma is eosinophilic asthma.

17. The use of any one of claims 1-7 or 9-15, wherein the patient has a blood eosinophil count of at least 300 cells/μl.

18. The use of any one of claims 1-8 or 10-17, wherein, the patient has a forced expiratory volume in one second (FEV_1) of at least 75% predicted value prior to the administration.

19. The use of any one of claims 1-18, wherein the patient has an asthma control questionnaire score of at least 1.5 prior to the administration

20. The use of any one of claims 1-9 or 11-19, wherein at least two doses of the medicament are administered to the patient.

21. The use of any one of claims 6 or 14-20, wherein the patient's ACQ-6 score decreases following administration of the medicament.

22. The use of any one of claims 6 or 14-21, wherein the ACQ-6 score is decreased by at least 0.5.

23. The use of claim 22, wherein the ACQ-6 score is decreased by at least 1.

24. The use of claim 23, wherein the ACQ-6 score is decreased by at least 2.

25. The use of any one of claims 1-24, wherein the patient uses high-dose inhaled corticosteroids (ICS).

26. The use of any one of claims 1-25, wherein the patient uses long-acting β2 agonists (LABA).

27. The use of any one of claims 1-26, wherein the patient has a history of exacerbations.

28. The use of claim 27, wherein the history of exacerbations comprises at least two exacerbations in the year prior to the administration of the medicament.

29. The use of claim 26 or 27, wherein the history of exacerbations comprises no more than six exacerbations in the year prior to the administration of the medicament.

30. The use of any one of claims 1-29, wherein the medicament is administered at about 2 mg to about 100 mg per dose.

31. The use of claim 30, wherein the medicament is administered at about 20 mg per dose.

32. The use of claim 30, wherein the medicament is administered at about 30 mg per dose.

33. The use of claim 30, wherein the medicament is administered at about 100 mg per dose.

34. The use of any one of claims 1-33, wherein the medicament is administered once every four weeks to once every twelve weeks.

35. The use of claim 34, wherein the medicament is administered once every four weeks.

36. The use of claim 34, wherein the medicament is administered once every eight weeks.

37. The use of claim 34, wherein the medicament is administered once every four weeks for twelve weeks and then once every eight weeks.

38. The use of any one of claims 1 to 37, wherein the medicament is administered parenterally.

39. The use of claim 38, wherein the medicament is administered subcutaneously.

40. The use of any one of claims 1 to 39, wherein the medicament is administered in addition to corticosteroid therapy.

41. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for improving an asthma questionnaire score in an asthmatic patient, comprising administering to an asthma patient 20-100 mg of the medicament, wherein the patient has an blood eosinophil count of at least 300 cells/μl prior to the administration.

42. The use of claim 41, comprising administering 20 mg of the medicament.

43. The use of claim 42, wherein the medicament is administered once every four weeks for twelve weeks and then once every eight weeks.

44. The use of claim 41, comprising administering 30 mg of the medicament.

45. The use of claim 44, wherein the medicament is administered once every four weeks for eight weeks and then once every eight weeks.

46. The use of claim 44, wherein the medicament is administered once every four weeks.

47. The use of claim 41, comprising administering 100 mg of the medicament.

48. The use of claim 47, wherein the medicament is administered once every four weeks for twelve weeks and then once every eight weeks.

49. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for treating asthma in an asthma patient, comprising administering to the patient a dose of at least 2 and less than 100 mg of the medicament.

50. The use of claim 49, wherein 20 mg of the medicament is administered.

51. The use of claim 49, wherein 30 mg of the medicament is administered.

52. The use of claim 49, wherein a dose of at least 20 and less than 100 mg of the medicament is administered.

53. The use of claim 49, wherein a dose of at least 30 and less than 100 mg of the medicament is administered.

54. The use of any one of claims 49-53, wherein administration of the medicament improves an asthma symptom in the patient.

55. The use of claim 54, wherein the symptom is selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue.

56. The use of any one of claims 49-55, wherein administration of the medicament decreases the patient's ACQ-6 score within four weeks of the first administration.

57. The use of any one of claims 49-56, wherein the administration is subcutaneous.